How Doctors Diagnose HPP Today: Important Biochemical Markers and Criteria

Hypophosphatasia (HPP) is a rare metabolic bone disease caused by mutations in the ALPL gene, leading to low activity of tissue-nonspecific alkaline phosphatase (TNSALP). Timely diagnosis is essential to guide management and improve outcomes. The Hypophosphatasia diagnosis guidelines 2026 emphasize a combination of biochemical tests, genetic analysis, clinical evaluation, and radiologic findings.

Key Biochemical Markers

1. Serum Alkaline Phosphatase (ALP) Activity

   • Persistently low ALP levels (below age- and sex-specific reference ranges) are the hallmark of HPP.
   • Mild decreases may occur in adults; profound reductions are more typical in infantile or perinatal forms.

2. Substrates of TNSALP
   Elevated levels of TNSALP substrates confirm reduced enzyme activity:

   • Pyridoxal 5′-phosphate (PLP)
     • PLP is the active form of vitamin B6.
     • Elevated serum PLP indicates impaired dephosphorylation by TNSALP.
   • Inorganic Pyrophosphate (PPi)
     • PPi accumulates extracellularly, inhibiting bone mineralization.
     • Measured indirectly or inferred from radiologic findings.
   • Phosphoethanolamine (PEA)
     • Urinary PEA is raised in many—but not all—cases, particularly infantile HPP.

3. Additional Labs

   • Calcium and phosphate: usually normal or mildly elevated calcium, normal phosphate.
   • Parathyroid hormone (PTH): variable; essential to rule out other metabolic bone disorders.
   • Vitamin D: check to exclude deficiency as a confounding factor.

Genetic Testing and Interpretation

• ALPL Gene Sequencing
  • Identifies pathogenic variants in the ALPL gene.
  • Over 400 mutations have been reported; each correlates with a spectrum of disease severity.
• Inheritance Patterns
  • Autosomal recessive inheritance predominates in severe (perinatal, infantile) forms.
  • Autosomal dominant variants often underlie milder, adult-onset HPP or odontohypophosphatasia.
• Variants of Uncertain Significance (VUS)
  • Requires correlation with biochemical and clinical data.
  • Family testing or functional assays may help clarify pathogenicity.

Clinical Evaluation

A thorough history and physical exam are vital. Look for:

• Skeletal Manifestations
  • Rickets-like changes in infants: widened growth plates, metaphyseal cupping.
  • Fractures or poorly healing stress fractures in children and adults.
• Dental Signs
  • Premature loss of deciduous teeth (“rootless” teeth).
  • Delayed tooth eruption or enamel hypoplasia.
• Neuromuscular Symptoms
  • Muscle weakness, hypotonia in infancy.
  • Chronic pain, difficulty walking in older patients.
• Other Features
  • Chondrocalcinosis (calcium pyrophosphate crystal deposition) in adults.
  • Nephrocalcinosis or renal stones if hypercalcemia is present.

Radiologic and Functional Studies

1. X-Rays

   • Infants: rickets-like changes, chest deformities (bell-shaped thorax), craniosynostosis.
   • Children/adolescents: metaphyseal dysplasia, fractures.
   • Adults: Looser’s zones (pseudofractures), osteopenia.

2. Bone Densitometry (DXA)

   • May show low bone mineral density, but values can be misleading due to short stature or deformities.

3. Bone Biopsy (Rarely Needed)

   • Demonstrates unmineralized osteoid; generally reserved for atypical or unclear cases.

Hypophosphatasia Diagnosis Guidelines 2026: Step-By-Step

The Hypophosphatasia diagnosis guidelines 2026 recommend an integrated approach:

1. Initial Screening

   • Measure serum ALP in any patient with unexplained fractures, rickets, premature tooth loss, or muscle weakness.
   • If ALP is low, proceed to substrate testing.

2. Confirmatory Biochemical Tests

   • Serum PLP
   • Urinary PEA (when available)
   • Rule out other causes of low ALP (e.g., malnutrition, hypothyroidism, medications).

3. Genetic Analysis

   • Sequence ALPL gene to identify pathogenic variants.
   • Parental testing to determine inheritance pattern.

4. Clinical Correlation

   • Match biochemical and genetic findings with patient’s signs and symptoms.
   • Assess disease severity to guide treatment decisions.

5. Radiologic Assessment

   • Use X-rays and, if needed, CT or MRI to evaluate bone changes and complications.

Differential Diagnosis

Before confirming HPP, exclude other conditions that may present similarly:

• Nutritional rickets (vitamin D deficiency)
• Hypophosphatemic rickets (e.g., X-linked hypophosphatemia)
• Osteogenesis imperfecta
• Other causes of low ALP (e.g., Wilson disease, anemia)

When to Refer to a Specialist

Consider specialist referral for:

• Infants with severe hypotonia, failure to thrive, or chest deformities.
• Children or adults with recurrent fractures or non-healing stress fractures.
• Any patient with confirmed ALPL mutation for discussion of enzyme replacement therapy (asfotase alfa) or clinical trials.

Treatment Implications

Accurate diagnosis informs management:

• Enzyme Replacement Therapy (ERT):
  • Asfotase alfa is approved for perinatal, infantile, and juvenile-onset HPP.
• Supportive Care:
  • Physical therapy for muscle strength and mobility.
  • Dental care to address premature tooth loss.
• Monitoring:
  • Regular biochemical monitoring (ALP, PLP).
  • Surveillance for complications (pulmonary, nephrocalcinosis).

Patient Empowerment and Next Steps

If you suspect HPP based on symptoms like unexplained fractures, early tooth loss, or persistent muscle weakness, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you gather relevant information before your medical appointment.

Summary

Early and accurate diagnosis of hypophosphatasia relies on:

• Low serum ALP activity
• Elevated substrates (PLP, PPi, PEA)
• Confirmation via ALPL gene sequencing
• Clinical and radiologic correlation

Following the Hypophosphatasia diagnosis guidelines 2026 ensures a comprehensive evaluation, timely referral, and appropriate management.

Speak to a doctor about any symptoms that could be serious or life-threatening.